Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Want to see JP:2395 full AI Analyst Report?
Top Page
Shin Nippon Biomedical Laboratories, Ltd.
(2395)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥1,163.00
▼(-28.30% Downside)
Action:Reiterated
Date:06/02/26
The score is anchored by moderate financial performance (profits remain solid but cash conversion and leverage are key risks) and is pulled down by bearish technicals (price below all major moving averages with negative MACD). Valuation is a clear offset, supported by a low P/E and a high dividend yield.
Positive Factors
High margins
Near-50% gross margin and ~14% net margin provide durable profitability for a specialized service provider. Strong margins create a buffer to absorb project variability, fund specialized facilities and scientific staff, and support reinvestment and shareholder returns even if top-line growth moderates.
Negative Factors
Rising leverage
Debt roughly equal to equity increases financial leverage and reduces balance‑sheet flexibility. Higher leverage raises interest costs and magnifies downside risk if margins or revenues deteriorate, constraining the firm's ability to invest or absorb shocks without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins
Near-50% gross margin and ~14% net margin provide durable profitability for a specialized service provider. Strong margins create a buffer to absorb project variability, fund specialized facilities and scientific staff, and support reinvestment and shareholder returns even if top-line growth moderates.
Read all positive factors
Shin Nippon Biomedical Laboratories, Ltd. (2395) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥45.42B
Dividend Yield2.79%
Average Volume (3M)231.41K
Price to Earnings (P/E)9.9
Beta (1Y)0.93
Revenue Growth0.34%
EPS Growth-7.27%
CountryJP
Employees1,457
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)121.63
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,640.00Price Target Upside1.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)97.55
Revenue Forecast (FY)¥37.81B
Shin Nippon Biomedical Laboratories, Ltd. Business Overview & Revenue Model
Company Description
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide arr...
How the Company Makes Money
The company primarily makes money by providing outsourced research services to customers developing new drugs and related biomedical products. Its core revenue stream is fee-for-service contract work in preclinical (non-clinical) stages, where cus...
Shin Nippon Biomedical Laboratories, Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.34B | 32.52B | 32.41B | 26.45B | 25.09B | 17.75B |
| Gross Profit | 16.62B | 15.83B | 16.57B | 14.28B | 13.05B | 9.69B |
| EBITDA | 8.86B | 6.09B | 8.83B | 8.98B | 9.49B | 9.49B |
| Net Income | 5.06B | 4.57B | 4.92B | 5.53B | 6.06B | 7.13B |
Balance Sheet | ||||||
| Total Assets | 89.07B | 105.06B | 92.42B | 76.30B | 58.31B | 39.38B |
| Cash, Cash Equivalents and Short-Term Investments | 11.57B | 18.54B | 12.03B | 10.61B | 10.53B | 7.00B |
| Total Debt | 36.58B | 41.26B | 34.61B | 26.33B | 18.93B | 9.28B |
| Total Liabilities | 53.17B | 61.57B | 52.33B | 42.14B | 31.95B | 19.66B |
| Stockholders Equity | 35.51B | 43.12B | 40.02B | 34.11B | 26.21B | 19.56B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.15B | -3.82B | -6.50B | -951.70M | 4.34B |
| Operating Cash Flow | 0.00 | 8.33B | 7.04B | 2.11B | 4.00B | 5.95B |
| Investing Cash Flow | 0.00 | -6.79B | -11.69B | -6.91B | -5.93B | -4.27B |
| Financing Cash Flow | 0.00 | 4.51B | 5.91B | 5.32B | 6.27B | -4.91B |
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis
Negative
1622.00
Price Trends
1289.42
Negative
1422.81
Negative
1531.27
Negative
Market Momentum
-57.19
Negative
32.27
Neutral
37.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2395, the sentiment is Negative. The current price of 1622 is above the 20-day moving average (MA) of 1126.90, above the 50-day MA of 1289.42, and above the 200-day MA of 1531.27, indicating a bearish trend. The MACD of -57.19 indicates Negative momentum. The RSI at 32.27 is Neutral, neither overbought nor oversold. The STOCH value of 37.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2395.
Shin Nippon Biomedical Laboratories, Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ¥133.13B | 17.06 | 5.94% | 3.34% | 4.94% | 26.92% | |
59 Neutral | ¥45.42B | 9.95 | ― | 2.79% | 0.34% | -7.27% | |
56 Neutral | ¥88.03B | 23.28 | ― | 2.31% | 3.35% | 74.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥4.83B | -1.45 | ― | 5.44% | -16.97% | -517.61% |
* Healthcare Sector Average
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,084.00
-244.35
-18.39%
JP:4694
BML
3,550.00
412.67
13.15%
JP:2183
Linical Co., Ltd.
208.00
-103.38
-33.20%
JP:4549
Eiken Chemical Co., Ltd.
2,634.00
604.61
29.79%
Shin Nippon Biomedical Laboratories, Ltd. Corporate Events
Shin Nippon Biomedical Laboratories Keeps Annual Dividend at ¥50 as CRO Business Hits Record Highs
May 29, 2026
Shin Nippon Biomedical Laboratories has approved a year-end dividend of ¥30 per share from retained earnings for shareholders of record on March 31, 2026, bringing total annual dividends for the fiscal year to ¥50 per share, unchanged fr...
SNBL backs U.S. launch build-out for migraine drug Atzumi after licensing talks stall
May 11, 2026
Shin Nippon Biomedical Laboratories has outlined a new commercialization strategy for Atzumi, an intranasal dihydroergotamine therapy developed by U.S. subsidiary Satsuma Pharmaceuticals for acute migraine in adults. After securing FDA approval an...
Shin Nippon Biomedical Laboratories Outlines FY2026 Results and Strategic Focus
May 11, 2026
Shin Nippon Biomedical Laboratories presented materials for its consolidated financial results briefing for the fiscal year ended March 31, 2026, outlining performance and outlook across its core businesses. The briefing covers the company’s...
SNBL Posts Flat Revenue, Lower Profits but Stronger Balance Sheet and Cash Ahead of FY2027 Growth Push
May 11, 2026
Shin Nippon Biomedical Laboratories reported fiscal 2026 revenue of ¥32.5 billion, up slightly year on year, while operating profit fell 11.1% to ¥2.65 billion and profit attributable to owners of the parent declined 7.3% to ¥4.57 b...
SNBL to Shift Meeting Leadership to Board Chair in Governance Revamp
Apr 30, 2026
Shin Nippon Biomedical Laboratories has moved to revise its Articles of Incorporation, shifting the role of convener and chair of both shareholder meetings and board meetings from the President and Representative Director to the Chairperson of the...
SNBL Revamps Top Management to Drive Long-Term Growth
Apr 30, 2026
Shin Nippon Biomedical Laboratories has announced a leadership reshuffle, appointing Hideyuki Hirama as Representative President while long-serving leader Ryoichi Nagata will become Representative Chairman, effective after shareholder approval at ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.